Vaccitech Newsroom
News & updates
Vaccitech Appoints Bill Enright as New Chief Executive Officer
Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID), announced today that it has appointed Bill Enright as its new Chief Executive Officer (CEO). Mr. Enright succeeds Tom Evans, MD who...
Vaccitech Appoints Chief Medical Officer to Oversee Development of Growing Clinical Pipeline of T Cell-Inducing Viral Vector Vaccines
Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent Cancer and Infectious Diseases, announces today that it has appointed Mariem Charafeddine as Chief Medical Officer. Mariem brings over 15 years’...
Vaccitech Universal flu vaccine passes Phase 2b clinical development milestones
Vaccitech initiates Phase 2b clinical studies for its MVA-NP+M1 universal flu vaccine (VTP-100) in Belgium and completes recruitment in Australia Oxford, United Kingdom – 5 June 2019: Vaccitech Ltd. announces that it has administered its pandemic universal influenza A...
ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform
AGE1.CR® Duck Cell Line - Safe and Well tolerated for Large-Scale Production Berlin, Germany, and Oxford, United Kingdom, May 15th, 2019: ProBioGen AG, a premier German service & technology provider for complex biologics and Vaccitech, Ltd., a spin-out company...
Vaccitech Awarded BARDA contract valued at $8.6M to conduct Phase II trial for Influenza Vaccine
Contract includes funding to conduct one of the largest influenza A challenge studies Vaccitech announced today that it has been awarded a contract valued at $8.6 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of...
Vaccitech receives £6M investment from GeneMatrix and Korea Investment Partners
Vaccitech will progress existing vaccine programs and the collaboration will combine Vaccitech’s know-how with GeneMatrix’s clinical network. Oxford, UK and Seoul, South Korea Vaccitech, a clinical stage developer of a universal flu vaccine and other vaccine-related...
Update: INVICTUS Study
Vaccitech has taken the decision not to proceed with season 2 of the current FLU007 (Invictus) study due to the changes recommended by the UK Government which directed the NHS to use FLUAD (adjuvanted TIV) vaccine in the 65 year old and over population in the 2018/19...
Vaccitech licenses MERS rights to Oxford University
CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines
New UK-China biotech collaboration to develop shingles vaccine
Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Vaccitech Limited, a UK-based company developing products to treat and prevent multiple infectious...
VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine
View/Download ASCO 2018 Poster